{"id":70266,"date":"2026-07-20T13:52:47","date_gmt":"2026-07-20T05:52:47","guid":{"rendered":"https:\/\/flcube.com\/?p=70266"},"modified":"2026-07-20T13:52:48","modified_gmt":"2026-07-20T05:52:48","slug":"bio-sincerity-secures-nmpa-approval-for-levetiracetam-extended-release-granules-pediatric-friendly-epilepsy-treatment-for-patients-with-swallowing-difficulties","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70266","title":{"rendered":"Bio-Sincerity Secures NMPA Approval for Levetiracetam Extended-Release Granules \u2013 Pediatric-Friendly Epilepsy Treatment for Patients with Swallowing Difficulties"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/301096:SHE\">SHE: 301096<\/a>) announced that its <strong>Category 2.2 modified drug Levetiracetam Extended-Release Granules<\/strong> has received <strong>approval from China&#8217;s National Medical Products Administration (NMPA)<\/strong> for use as <strong>adjunctive therapy in the treatment of partial-onset seizures<\/strong> in epilepsy patients aged <strong>12 years and older<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-approval-overview\" class=\"wp-block-heading\">Regulatory Approval Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Authority<\/strong><\/td><td>China National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Product Classification<\/strong><\/td><td>Category 2.2 modified drug (new formulation of existing active ingredient)<\/td><\/tr><tr><td><strong>Approved Indication<\/strong><\/td><td>Adjunctive therapy for partial-onset seizures in epilepsy patients \u226512 years<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>20 Jul 2026<\/td><\/tr><tr><td><strong>Market Exclusivity<\/strong><\/td><td>First levetiracetam extended-release granule formulation approved in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-innovation-amp-clinical-advantages\" class=\"wp-block-heading\">Product Innovation &amp; Clinical Advantages<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Active Ingredient:<\/strong> Levetiracetam \u2013 widely used antiepileptic medication with established safety profile in pediatric populations<\/li>\n\n\n\n<li><strong>Novel Formulation:<\/strong> Extended-release granules designed specifically for <strong>pediatric patients and individuals with swallowing difficulties<\/strong><\/li>\n\n\n\n<li><strong>Key Differentiators vs. Existing Formulations:<\/strong><\/li>\n\n\n\n<li>Superior to immediate-release tablets: Once-daily dosing improves compliance<\/li>\n\n\n\n<li>Superior to extended-release tablets: Granule format eliminates swallowing challenges<\/li>\n\n\n\n<li>Flexible administration: Can be mixed with food or liquid for easier ingestion<\/li>\n\n\n\n<li><strong>Clinical Benefits:<\/strong> Enhanced medication adherence, consistent drug delivery, and improved quality of life for vulnerable patient populations<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-target-patient-population-analysis\" class=\"wp-block-heading\">Target Patient Population Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Patient Segment<\/th><th>Current Challenges<\/th><th>Bio-Sincerity Solution<\/th><\/tr><\/thead><tbody><tr><td><strong>Pediatric Patients (12+ years)<\/strong><\/td><td>Difficulty swallowing tablets; poor compliance with multiple daily doses<\/td><td>Granule formulation easily mixed with food; once-daily extended-release dosing<\/td><\/tr><tr><td><strong>Patients with Dysphagia<\/strong><\/td><td>Inability to safely swallow solid oral dosage forms<\/td><td>Granule format eliminates choking risk and swallowing discomfort<\/td><\/tr><tr><td><strong>Non-compliant Patients<\/strong><\/td><td>Complex dosing regimens leading to treatment gaps<\/td><td>Simplified once-daily administration improves adherence<\/td><\/tr><tr><td><strong>Caregiver-Dependent Patients<\/strong><\/td><td>Difficulty administering traditional formulations<\/td><td>Easy mixing with food\/beverages simplifies caregiver burden<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-opportunity-amp-commercial-strategy\" class=\"wp-block-heading\">Market Opportunity &amp; Commercial Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Epilepsy Prevalence:<\/strong> China has an estimated 9 million epilepsy patients, with ~30% being pediatric cases<\/li>\n\n\n\n<li><strong>Treatment Gap:<\/strong> Significant unmet need for age-appropriate, swallowing-friendly antiepileptic formulations<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Levetiracetam market dominated by immediate-release and extended-release tablets; no granule formulations previously available in China<\/li>\n\n\n\n<li><strong>Market Potential:<\/strong> Annual levetiracetam market in China exceeds \u00a52 billion ($280 million), with premium pricing potential for innovative formulations<\/li>\n\n\n\n<li><strong>Commercial Launch:<\/strong> Expected Q4 2026 through Bio-Sincerity&#8217;s established hospital and retail pharmacy distribution channels<\/li>\n\n\n\n<li><strong>Reimbursement Strategy:<\/strong> Category 2.2 classification may qualify for favorable provincial reimbursement listing due to clear clinical advantages<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial prospects for Levetiracetam Extended-Release Granules. Actual results may differ due to risks including market adoption, competitive dynamics, and reimbursement decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><br><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u767e\u8bda\u533b\u836f\uff1a\u5173\u4e8e2\u7c7b\u6539\u826f\u578b\u65b0\u836f\u5de6\u4e59\u62c9\u897f\u5766\u7f13\u91ca\u9897\u7c92\u83b7\u5f97\u836f\u54c1\u6ce8\u518c\u8bc1\u4e66\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u767e\u8bda\u533b\u836f\uff1a\u5173\u4e8e2\u7c7b\u6539\u826f\u578b\u65b0\u836f\u5de6\u4e59\u62c9\u897f\u5766\u7f13\u91ca\u9897\u7c92\u83b7\u5f97\u836f\u54c1\u6ce8\u518c\u8bc1\u4e66\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-b45d95ce-de4d-42e4-9740-25e214dd4dd7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u767e\u8bda\u533b\u836f\uff1a\u5173\u4e8e2\u7c7b\u6539\u826f\u578b\u65b0\u836f\u5de6\u4e59\u62c9\u897f\u5766\u7f13\u91ca\u9897\u7c92\u83b7\u5f97\u836f\u54c1\u6ce8\u518c\u8bc1\u4e66\u7684\u516c\u544a.pdf\">\u767e\u8bda\u533b\u836f\uff1a\u5173\u4e8e2\u7c7b\u6539\u826f\u578b\u65b0\u836f\u5de6\u4e59\u62c9\u897f\u5766\u7f13\u91ca\u9897\u7c92\u83b7\u5f97\u836f\u54c1\u6ce8\u518c\u8bc1\u4e66\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u767e\u8bda\u533b\u836f\uff1a\u5173\u4e8e2\u7c7b\u6539\u826f\u578b\u65b0\u836f\u5de6\u4e59\u62c9\u897f\u5766\u7f13\u91ca\u9897\u7c92\u83b7\u5f97\u836f\u54c1\u6ce8\u518c\u8bc1\u4e66\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b45d95ce-de4d-42e4-9740-25e214dd4dd7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that its Category 2.2 modified drug Levetiracetam&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[3775,15,3975],"class_list":["post-70266","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-bio-sincerity-pharmaceutical-technology","tag-product-approvals","tag-she-301096"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bio-Sincerity Secures NMPA Approval for Levetiracetam Extended-Release Granules \u2013 Pediatric-Friendly Epilepsy Treatment for Patients with Swallowing Difficulties - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that its Category 2.2 modified drug Levetiracetam Extended-Release Granules has received approval from China&#039;s National Medical Products Administration (NMPA) for use as adjunctive therapy in the treatment of partial-onset seizures in epilepsy patients aged 12 years and older.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70266\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Sincerity Secures NMPA Approval for Levetiracetam Extended-Release Granules \u2013 Pediatric-Friendly Epilepsy Treatment for Patients with Swallowing Difficulties\" \/>\n<meta property=\"og:description\" content=\"Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that its Category 2.2 modified drug Levetiracetam Extended-Release Granules has received approval from China&#039;s National Medical Products Administration (NMPA) for use as adjunctive therapy in the treatment of partial-onset seizures in epilepsy patients aged 12 years and older.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70266\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-20T05:52:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-20T05:52:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70266#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70266\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio-Sincerity Secures NMPA Approval for Levetiracetam Extended-Release Granules \u2013 Pediatric-Friendly Epilepsy Treatment for Patients with Swallowing Difficulties\",\"datePublished\":\"2026-07-20T05:52:47+00:00\",\"dateModified\":\"2026-07-20T05:52:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70266\"},\"wordCount\":409,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Bio-Sincerity Pharmaceutical Technology\",\"Product approvals\",\"SHE: 301096\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70266#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70266\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70266\",\"name\":\"Bio-Sincerity Secures NMPA Approval for Levetiracetam Extended-Release Granules \u2013 Pediatric-Friendly Epilepsy Treatment for Patients with Swallowing Difficulties - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-20T05:52:47+00:00\",\"dateModified\":\"2026-07-20T05:52:48+00:00\",\"description\":\"Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that its Category 2.2 modified drug Levetiracetam Extended-Release Granules has received approval from China's National Medical Products Administration (NMPA) for use as adjunctive therapy in the treatment of partial-onset seizures in epilepsy patients aged 12 years and older.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70266#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70266\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70266#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Sincerity Secures NMPA Approval for Levetiracetam Extended-Release Granules \u2013 Pediatric-Friendly Epilepsy Treatment for Patients with Swallowing Difficulties\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio-Sincerity Secures NMPA Approval for Levetiracetam Extended-Release Granules \u2013 Pediatric-Friendly Epilepsy Treatment for Patients with Swallowing Difficulties - Insight, China&#039;s Pharmaceutical Industry","description":"Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that its Category 2.2 modified drug Levetiracetam Extended-Release Granules has received approval from China's National Medical Products Administration (NMPA) for use as adjunctive therapy in the treatment of partial-onset seizures in epilepsy patients aged 12 years and older.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70266","og_locale":"en_US","og_type":"article","og_title":"Bio-Sincerity Secures NMPA Approval for Levetiracetam Extended-Release Granules \u2013 Pediatric-Friendly Epilepsy Treatment for Patients with Swallowing Difficulties","og_description":"Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that its Category 2.2 modified drug Levetiracetam Extended-Release Granules has received approval from China's National Medical Products Administration (NMPA) for use as adjunctive therapy in the treatment of partial-onset seizures in epilepsy patients aged 12 years and older.","og_url":"https:\/\/flcube.com\/?p=70266","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-20T05:52:47+00:00","article_modified_time":"2026-07-20T05:52:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70266#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70266"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio-Sincerity Secures NMPA Approval for Levetiracetam Extended-Release Granules \u2013 Pediatric-Friendly Epilepsy Treatment for Patients with Swallowing Difficulties","datePublished":"2026-07-20T05:52:47+00:00","dateModified":"2026-07-20T05:52:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70266"},"wordCount":409,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Bio-Sincerity Pharmaceutical Technology","Product approvals","SHE: 301096"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70266#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70266","url":"https:\/\/flcube.com\/?p=70266","name":"Bio-Sincerity Secures NMPA Approval for Levetiracetam Extended-Release Granules \u2013 Pediatric-Friendly Epilepsy Treatment for Patients with Swallowing Difficulties - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-20T05:52:47+00:00","dateModified":"2026-07-20T05:52:48+00:00","description":"Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that its Category 2.2 modified drug Levetiracetam Extended-Release Granules has received approval from China's National Medical Products Administration (NMPA) for use as adjunctive therapy in the treatment of partial-onset seizures in epilepsy patients aged 12 years and older.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70266#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70266"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70266#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio-Sincerity Secures NMPA Approval for Levetiracetam Extended-Release Granules \u2013 Pediatric-Friendly Epilepsy Treatment for Patients with Swallowing Difficulties"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70266"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70266\/revisions"}],"predecessor-version":[{"id":70270,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70266\/revisions\/70270"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}